Compare Stocks → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AEMDOTCMKTS:ARTHNASDAQ:MOTSNASDAQ:NVCN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEMDAethlon Medical$1.73-1.1%$1.75$1.40▼$7.20$4.53M1.898,599 shs6,749 shsARTHArch Therapeutics$1.82-6.2%$2.74$0.39▼$18.00$8.60M3.576,531 shs5,080 shsMOTSMotus GI$0.42-4.6%$0.70$0.40▼$23.40$2.09M1.341.73 million shs69,102 shsNVCNNeovasc$30.03$29.69$4.59▼$30.07$82.28M1.756,993 shs1 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEMDAethlon Medical-1.14%+5.49%-1.14%-20.64%-54.47%ARTHArch Therapeutics-6.44%-4.97%-13.57%-73.35%-42.56%MOTSMotus GI-3.64%-19.98%-42.22%-71.30%-96.92%NVCNNeovasc0.00%0.00%0.00%0.00%+2.95%Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEMDAethlon Medical1.7446 of 5 stars3.53.00.00.02.30.00.6ARTHArch TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMOTSMotus GI2.5849 of 5 stars3.55.00.00.02.70.00.6NVCNNeovascN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEMDAethlon Medical3.00Buy$10.00478.03% UpsideARTHArch TherapeuticsN/AN/AN/AN/AMOTSMotus GI3.00Buy$28.886,839.44% UpsideNVCNNeovascN/AN/AN/AN/ACurrent Analyst RatingsLatest ARTH, AEMD, NVCN, and MOTS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/4/2024AEMDAethlon MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$23.00 ➝ $10.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEMDAethlon Medical$570K7.95N/AN/A$6.56 per share0.26ARTHArch Therapeutics$80K107.54N/AN/A($2.43) per share-0.75MOTSMotus GI$320K6.54N/AN/A$1.74 per share0.24NVCNNeovasc$3.81M21.60N/AN/A$5.77 per share5.20Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEMDAethlon Medical-$12.03M-$4.99N/AN/AN/AN/A-106.28%-86.60%6/26/2024 (Estimated)ARTHArch Therapeutics-$6.98MN/A0.000.17N/A-6,809.45%N/A-386.74%5/20/2024 (Estimated)MOTSMotus GI-$12.87M-$28.55N/A∞N/A-4,033.54%-3,413.36%-110.70%5/8/2024 (Estimated)NVCNNeovasc-$41.20M-$15.08N/A∞N/A-1,082.92%-127.25%-80.31%N/ALatest ARTH, AEMD, NVCN, and MOTS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/20/2024Q1 2024ARTHArch TherapeuticsN/A-$0.57-$0.57-$0.57N/A$0.05 million2/14/2024Q3 2024AEMDAethlon Medical-$1.23-$1.37-$0.14-$1.37N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEMDAethlon MedicalN/AN/AN/AN/AN/AARTHArch TherapeuticsN/AN/AN/AN/AN/AMOTSMotus GIN/AN/AN/AN/AN/ANVCNNeovascN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEMDAethlon MedicalN/A3.933.93ARTHArch TherapeuticsN/A0.160.04MOTSMotus GI0.461.761.69NVCNNeovasc0.802.962.85OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEMDAethlon Medical1.99%ARTHArch Therapeutics6.91%MOTSMotus GI20.06%NVCNNeovasc1.64%Insider OwnershipCompanyInsider OwnershipAEMDAethlon Medical4.00%ARTHArch Therapeutics4.50%MOTSMotus GI1.57%NVCNNeovascN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAEMDAethlon Medical152.62 million2.52 millionOptionableARTHArch Therapeutics84.74 million4.53 millionNot OptionableMOTSMotus GI435.03 million4.95 millionNot OptionableNVCNNeovasc492.74 millionN/ANot OptionableARTH, AEMD, NVCN, and MOTS HeadlinesSourceHeadlineTop Small-Cap Stocks for May 2023 - Investopedianews.google.com - May 13 at 9:38 AMFDA accepts application for Roche's Vabysmo for the - GlobeNewswirenews.google.com - May 9 at 2:18 AMNew treatment option opens avenues in geographic atrophy - Healionews.google.com - May 8 at 9:18 PMPachychoroid neovasculopathy has clinical properties that differ ... - Nature.comnews.google.com - May 8 at 9:18 PMThe NOD audit provides data and insights for the management for ... - Modern Retinanews.google.com - May 8 at 9:18 PMShockwave Medical Reports First Quarter 2023 Financial Results - GlobeNewswirenews.google.com - May 8 at 4:17 PMHeart valve repair and replacement devices market size to grow by ... - Benzinganews.google.com - May 5 at 9:03 PMASCRS: Prediction of imminent conversion to neovascular AMD ... - Optometry Timesnews.google.com - May 5 at 4:02 PMFaricimab in Treatment-Resistant nARMD | OPTH - Dove Medical Pressnews.google.com - May 5 at 12:24 AMRestoring vision through retinal ganglion cell repopulation - Ophthalmology Times Europenews.google.com - May 5 at 12:24 AMSTAR Trial: Surgery Not Superior to Pneumatic Displacement for ... - MD Magazinenews.google.com - May 4 at 7:24 PMThe NOD audit: Insights into the current state of management for ... - Nature.comnews.google.com - May 4 at 8:40 AMOn the horizon: Treatments for both forms of AMD - Ophthalmology Times Europenews.google.com - May 3 at 10:56 AMBiosimilar Ranibizumab Displays Comparable Safety, Efficacy to ... - The Center for Biosimilarsnews.google.com - April 28 at 3:22 PMReal World Evidence Supporting GA Therapy Management Strategies - AJMC.com Managed Markets Networknews.google.com - April 28 at 10:22 AMLow-vision services improve vision, quality of life in patients with ... - Healionews.google.com - April 28 at 10:22 AMNew Vabysmo data suggest greater retinal drying versus aflibercept ... - GlobeNewswirenews.google.com - April 25 at 6:55 PMNew treatment tackles both forms of AMD - Ophthalmology Timesnews.google.com - April 25 at 6:55 PMPrice Variation in Economic Evaluations of Infliximab Could ... - The Center for Biosimilarsnews.google.com - April 25 at 1:32 AM1-Year Outcomes of Phase 3 Study for SB15, Proposed biosimilar to Eylea (aflibercept), Presented at the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting - Yahoo Financenews.google.com - April 25 at 1:32 AMAccel Research expands reach with acquisition of two Florida trial ... - FierceBiotechnews.google.com - April 24 at 3:16 PMReport: Boston Scientific considering massive deal to acquire ... - Cardiovascular Businessnews.google.com - April 24 at 3:16 PMBoston Sci Rumored to Be Interested in Acquiring Shockwave - Medical Device and Diagnostics Industrynews.google.com - April 21 at 4:24 PMThe Future of the Structural Heart Disease Intervention Devices ... - Digital Journalnews.google.com - April 21 at 10:58 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAethlon MedicalNASDAQ:AEMDAethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.Arch TherapeuticsOTCMKTS:ARTHArch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.Motus GINASDAQ:MOTSMotus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. Motus GI Holdings, Inc. was founded in 2008 and is based in Fort Lauderdale, Florida.NeovascNASDAQ:NVCNNeovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.